Welcome to
Endpoints News’
manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
The Government of Canada is contributing
$62 million
to Entos Pharmaceuticals to build a 103,000 square-foot manufacturing and R&D facility in Edmonton, Alberta. The build will cost a total of $198.5 million and will hire 90 new employees, according to a Tuesday release.
CDMO Vetter is
investing
over €150 million ($163 million) to expand its warehouse in Ravensburg, Germany. The move will increase its cool storage services, according to a Tuesday release.
The European Commission has
launched
a new regulation called the Critical Medicines Act to improve the continent’s pharma supply chains. The act will increase or improve EU manufacturing capacity for raw materials and drug products, among others. Some member states will or have received financial support to improve manufacturing, according to a Monday release.
The Noramco Group is investing
$25 million
into its factory in Whippany, NJ, to expand manufacturing of sterile injectables, syringes and vials, the company said Monday.
Scimplify has secured
$40 million
in a Series B raise, which will be used to scale up its chemical manufacturing platform, the company announced Wednesday.
LGM Pharma is investing
over
$6 million
to expand its Rosenberg, TX, manufacturing site for making liquid, semi-solid and suppository drug products, the company said Wednesday.
WuXi XDC has
signed
a memorandum of understanding with the South Korean biotech AbTis, the company said Tuesday. WuXi will provide its ADC discovery services and manufacturing platform and AbTis will bring its conjugation tech.
Emergent BioSolutions and Swiss vaccine company Rocketvax
have entered into a new
partnership
. Emergent will manufacture and commercialize four of Rocketvax’s clinical stage assets, the companies said Wednesday.
RoslinCT and Ayrmid Pharma
announced
their intent to partner on the production of the cell therapy Omisirge for blood cancer, the companies announced Tuesday. RoslinCT will tech transfer and commercially make the drug at its site in Hopkinton, MA.